Source 1review1998Leukemia & lymphoma/Leukemia and lymphoma
Toolkit/CrmA overexpression
CrmA overexpression
Also known as: cowpoxvirus protein CrmA
Taxonomy: Mechanism Branch / Architecture. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
Furthermore, overexpression of the caspase inhibitor, cowpoxvirus protein CrmA, also protected target T cells from being killed by myeloma cells, identifying Fas/FasL mediated signaling as the effector pathway utilized by malignant plasma cells.
Usefulness & Problems
Why this is useful
CrmA overexpression is described as protecting target T cells from being killed by myeloma cells. In the abstract, this is used to identify Fas/FasL-mediated signaling as the operative effector pathway.; probing caspase-dependent apoptosis pathways; functionally testing whether killing depends on Fas/FasL-mediated signaling
Source:
CrmA overexpression is described as protecting target T cells from being killed by myeloma cells. In the abstract, this is used to identify Fas/FasL-mediated signaling as the operative effector pathway.
Source:
probing caspase-dependent apoptosis pathways
Source:
functionally testing whether killing depends on Fas/FasL-mediated signaling
Problem solved
It helps distinguish whether observed cell killing proceeds through a caspase-dependent Fas/FasL pathway in the described system.; provides a mechanistic perturbation that can protect target cells from apoptosis in the described assay context
Source:
It helps distinguish whether observed cell killing proceeds through a caspase-dependent Fas/FasL pathway in the described system.
Source:
provides a mechanistic perturbation that can protect target cells from apoptosis in the described assay context
Problem links
provides a mechanistic perturbation that can protect target cells from apoptosis in the described assay context
LiteratureIt helps distinguish whether observed cell killing proceeds through a caspase-dependent Fas/FasL pathway in the described system.
Source:
It helps distinguish whether observed cell killing proceeds through a caspase-dependent Fas/FasL pathway in the described system.
Taxonomy & Function
Primary hierarchy
Mechanism Branch
Architecture: A reusable architecture pattern for arranging parts into an engineered system.
Techniques
No technique tags yet.
Target processes
signalingImplementation Constraints
cofactor dependency: cofactor requirement unknownencoding mode: genetically encodedimplementation constraint: context specific validationoperating role: regulator
The reported use requires overexpression of the cowpoxvirus caspase inhibitor in target T cells and an assay that measures myeloma-cell-induced killing.; requires overexpression in target cells; depends on a context where caspase-mediated apoptosis is being assayed
The abstract does not show that CrmA overexpression is a therapeutic solution or a general-purpose apoptosis blocker across settings. It is only presented as a mechanistic protection strategy in vitro.; evidence is limited to pathway assignment in the described in vitro context; the abstract does not describe delivery, expression system, or broader applicability
Validation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Supporting Sources
Ranked Claims
Blocking Fas on target T cells or neutralizing FasL on myeloma cells protects target T cells from programmed cell death, supporting Fas/FasL-mediated signaling as the effector pathway in the described myeloma system.
Overexpression of the caspase inhibitor CrmA protected target T cells from killing by myeloma cells, supporting assignment of the killing mechanism to Fas/FasL-mediated signaling.
Approval Evidence
1 source1 linked approval claimfirst-pass slug crma-overexpression
Furthermore, overexpression of the caspase inhibitor, cowpoxvirus protein CrmA, also protected target T cells from being killed by myeloma cells, identifying Fas/FasL mediated signaling as the effector pathway utilized by malignant plasma cells.
Source:
mechanistic interference summarysupports
Overexpression of the caspase inhibitor CrmA protected target T cells from killing by myeloma cells, supporting assignment of the killing mechanism to Fas/FasL-mediated signaling.
Source:
Comparisons
Source-stated alternatives
The abstract mentions Fas-blocking monoclonal antibody and FasL-neutralizing monoclonal antibody as alternative pathway-interference approaches.
Source:
The abstract mentions Fas-blocking monoclonal antibody and FasL-neutralizing monoclonal antibody as alternative pathway-interference approaches.
Source-backed strengths
used in the abstract as a mechanistic discriminator for the effector pathway; associated with protection of target T cells from killing by myeloma cells
Source:
used in the abstract as a mechanistic discriminator for the effector pathway
Source:
associated with protection of target T cells from killing by myeloma cells
Compared with Fas-blocking monoclonal antibody
The abstract mentions Fas-blocking monoclonal antibody and FasL-neutralizing monoclonal antibody as alternative pathway-interference approaches.
Shared frame: source-stated alternative in extracted literature
Strengths here: used in the abstract as a mechanistic discriminator for the effector pathway; associated with protection of target T cells from killing by myeloma cells.
Relative tradeoffs: evidence is limited to pathway assignment in the described in vitro context; the abstract does not describe delivery, expression system, or broader applicability.
Source:
The abstract mentions Fas-blocking monoclonal antibody and FasL-neutralizing monoclonal antibody as alternative pathway-interference approaches.
Compared with FasL-neutralizing monoclonal antibody
The abstract mentions Fas-blocking monoclonal antibody and FasL-neutralizing monoclonal antibody as alternative pathway-interference approaches.
Shared frame: source-stated alternative in extracted literature
Strengths here: used in the abstract as a mechanistic discriminator for the effector pathway; associated with protection of target T cells from killing by myeloma cells.
Relative tradeoffs: evidence is limited to pathway assignment in the described in vitro context; the abstract does not describe delivery, expression system, or broader applicability.
Source:
The abstract mentions Fas-blocking monoclonal antibody and FasL-neutralizing monoclonal antibody as alternative pathway-interference approaches.
Ranked Citations
- 1.